pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 9·1 min read
save

Endpoints Weekly highlights biotech company models, a quirky startup story, and earnings season updates

May 9, 2026·read at Endpoints ↗Neutral

The latest edition of Endpoints Weekly introduces a look at emerging biotech company structures, noting how new models are reshaping the industry.

It also features a light‑hearted piece about a startup that used an unconventional approach involving waste‑derived technology, described as the "super poop" story.

In addition, the newsletter provides a roundup of the ongoing earnings season, with original reporting and exclusive insights that are not available elsewhere.

Readers are invited to sign up for free access to a limited number of articles and to subscribe for full newsletter delivery.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Biotech’s new company model; The super poop behind a startup launch; and more”

read at Endpoints ↗
88 words · retrieved May 9
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Vyome Holdings, Inc

related stories

  • Oct 7MimiVax's cancer vaccine for glioblastoma narrowly misses Phase 2b goalEndpoints
  • Sep 28Mirum reports Phase 3 victory for acquired hepatitis D medEndpoints
  • Sep 9Key research behind orexin and narcolepsy wins Lasker AwardEndpoints
  • Aug 18Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy liftingEndpoints
  • Aug 13'Incorrect and misleading' data prompted decision to pull Tavneos in EuropeEndpoints